The crystal structure of the complex of the anticancer prodrug 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin (CPT-11) with Torpedo californica acetylcholinesterase provides a molecular explanation for its cholinergic action

Molecular Pharmacology

Volumn 67, Issue 6, 2005, Pages 1874-1881

  Harel, Michal ^a   Hyatt, Janice L ^b   Brumshtein, Boris ^a   Morton, Christopher L ^b   Yoon, Kyoung Jin P ^b   Wadkins, Randy M ^c   Silman, Israel ^a   Sussman, Joel L ^a   Potter, Philip M ^b  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ACETYLCHOLINESTERASE; CARBOXYLESTERASE; CHOLINESTERASE; DONEPEZIL; IRINOTECAN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CHOLINESTERASE INHIBITOR; DRUG DERIVATIVE; PRODRUG;

ARTICLE; CHEMICAL BOND; CHOLINERGIC ACTIVITY; CHOLINESTERASE INHIBITION; CRYSTAL STRUCTURE; DRUG BINDING SITE; DRUG DETERMINATION; DRUG HYDROLYSIS; DRUG PROTEIN BINDING; ENZYME ACTIVE SITE; ENZYME INHIBITION; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; TORPEDO CALIFORNICA; X RAY CRYSTALLOGRAPHY; ANIMAL; CHEMISTRY; CRYSTALLIZATION; HUMAN; METABOLISM; TORPEDO;

ACETYLCHOLINESTERASE; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CHOLINESTERASE INHIBITORS; CRYSTALLIZATION; CRYSTALLOGRAPHY, X-RAY; HUMANS; PRODRUGS; TORPEDO;

EID: 21744460401     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.104.009944     Document Type: Article

References (40)

1. Abigerges D, Chabot GG, Armand JP, Herait P, Gouyette A, and Gandia D (1995) Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 13:210-221.
2. Bencharit S, Morton CL, Howard-Williams EL, Danks MK, Potter PM, and Redinbo MR (2002) Structural insights into CPT-11 activation by mammalian carboxylesterases. Nat Struct Biol 9:337-342.
3. Blandizzi C, Danesi R, De Paolis B, Di Paolo A, Colucci R, Falcone A, and Del Tacca M (2002) Cholinergic toxic syndrome by the anticancer drug irinotecan: acetylcholinesterase does not play a major role. Clin Pharmacol Ther 71:263-271.
4. Blandizzi C, De Paolis B, Colucci R, Lazzeri G, Baschiera F, and Del Tacca M (2001) Characterization of a novel mechanism accounting for the adverse cholinergic effects of the anticancer drug irinotecan. Br J Pharmacol 132:73-84.
5. Brunger AT, Adams PD, Clore GM, DeLano WL, Gros P, Grosse Kunstleve RW, Jiang JS, Kuszewski J, Nilges M, Pannu NS, et al. (1998) Crystallography & NMR system: a new software suite for macromolecular structure determination. Acta Cryst 54:905-921.
6. Bugat R, Rougier P, Douillard JY, Brunet R, Ychou M, Adenis A, Marty M, Seitz JF, Conroy T, Merouche Y, et al. (1995) Efficacy of irinotecan HCl (CPT11) in patients with metastatic colorectal cancer after progression while receiving a 5-FU-based chemotherapy. Proc Annu Meet Am Soc Clin Oncol 14:A567.
7. Doctor BP, Toker L, Roth E, and Silman I (1987) Microtiter assay for acetylcholinesterase. Anal Biochem 166:399-403.
8. Dodds HM and Rivory LP (1999) The mechanism for the inhibition of acetylcholinesterases by irinotecan (CPT-11). Mol Pharmacol 56:1346-1353.
9. Ellman GL, Courtney KD, Anders V, and Featherstone RM (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7:88-95.
10. Esnouf RM (1997) An extensively modified version of MolScript that includes greatly enhanced coloring capabilities. J Mol Graph Model 15:132-134.
11. Furman WL, Stewart CF, Poquette CA, Pratt CB, Santana VM, Zamboni WC, Bowman LC, Ma MK, Hoffer FA, Meyer WH, et al. (1999) Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol 17:1815-1824.
12. Gandia D, Abigerges D, Armand JP, Chabot G, Da Costa L, De Forni M, Mathieu-Boue A, and Herait P (1993) CPT-11-induced cholinergic effects in cancer patients. J Clin Oncol 11:196-197.
13. Harel M, Kleywegt GJ, Ravelli RB, Silman I, and Sussman JL (1995) Crystal structure of an acetylcholinesterase-fasciculin complex: interaction of a three-fingered toxin from snake venom with its target. Structure 3:1355-1366.
14. Harel M, Schalk I, Ehret-Sabatier L, Bouet F, Goeldner M, Hirth C, Axelsen PH, Silman I, and Sussman JL (1993) Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase. Proc Natl Acad Sci USA 90:9031-9035.
15. Hsiang YH and Liu LF (1988) Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48:1722-1726.
16. Jones TA, Zou JY, Cowan SW, and Kjeldgaard (1991) Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr A 47:110-119.
17. Kabsch W (1993) Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants. J Appl Cryst 26:795-800.
18. Kawato Y, Sekiguchi M, Akahane K, Tsutomi Y, Hirota Y, Kuga H, Suzuki W, Hakusui H, and Sato K (1993) Inhibitory activity of camptothecin derivatives against acetylcholinesterase in dogs and their binding activity to acetylcholine receptors in rats. J Pharm Pharmacol 45:444-448.
19. Khanna R, Morton CL, Danks MK, and Potter PM (2000) Proficient metabolism of CPT-11 by a human intestinal carboxylesterase. Cancer Res 60:4725-4728.
20. Kraulis PJ (1991) MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J Appl Cryst 24:946-950.
21. Kryger G, Silman I, and Sussman JL (1999) Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs. Structure 7:297-307.
22. Merritt EA and Bacon DJ (1997) Raster 3D: Photorealistic molecular graphics. Methods Enzymol 277:505-524.
23. Morton CL, Wadkins RM, Danks MK, and Potter PM (1999) CPT-11 is a potent inhibitor of acetylcholinesterase but is rapidly catalyzed to SN-38 by butyrylcholinesterase. Cancer Res 59:1458-1463.
24. Nicolet Y, Lockridge O, Masson P, Fontecilla-Camps JC, and Nachon F (2003) Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products. J Biol Chem 278:41141-41147.
25. Petit RG, Rothenberg ML, Mitchell EP, Compton LD, and Miller LL (1997) Cholinergic symptoms following CPT-11 infusion in a phase II multicenter trial of 250 mg/m2 irinotecan (CRT-11) given every two weeks. Proceedings of the 33th Annual Meeting of the American Society for Clinical Oncology; 1997 May 17-20; Denver, Colorado. 16:A953.
26. Pommier Y, Jaxel C, Kerigan D, and Kohn KW (1991) Structure activity relationship of topoisomerase I inhibition by camptothecin derivatives: evidence for the existence of a ternary complex, in DNA Topoisomerases in Cancer (Potmesil M and Kohn KW eds) pp 121-132, Oxford University Press, New York.
27. Potter PM, Pawlik CA, Morton CL, Naeve CW, and Danks MK (1998) Isolation and partial characterization of a cDNA encoding a rabbit liver carboxylesterase that activates the prodrug irinotecan (CPT-11). Cancer Res 52:2646-2651.
28. Raves ML, Harel M, Pang YP, Silman I, Kozikowski AP, and Sussman JL (1997) Structure of acetylcholinesterase complexed with the nootropic alkaloid, (-)-huperzine A. Nat Struct Biol 4:57-63.
29. Rivory LP, Haaz M-C, Canal P, Lokiec F, Armand J-P, and Robert J (1997) Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in Phase I/II trials. Clin Cancer Res 3:1261-1266.
30. Saijo N (2003) Progress in treatment of small-cell lung cancer: role of CPT-11. Br J Cancer 89:2178-2183.
31. Silman I, Harel M, Axelsen P, Raves M, and Sussman JL (1994) Three-dimensional structures of acetylcholinesterase and of its complexes with anticholinesterase agents. Biochem Soc Trans 22:745-749.
32. Simon M, Argiris A, and Murren JR (2004) Progress in the therapy of small cell lung cancer. Crit Rev Oncol Hematol 49:119-133.
33. Sussman JL, Harel M, Frolow F, Oefner C, Goldman A, Toker L, and Silman I (1991) Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein. Science (Wash DC) 253:872-879.
34. Sussman JL, Harel M, Frolow F, Varon L, Toker L, Futerman AH, and Silman I (1988) Purification and crystallization of a dimeric form of acetylcholinesterase from Torpedo californica subsequent to solubilization with phosphatidylinositol-specific phospholipase C. J Mol Biol 203:821-823.
35. Sussman JL, Harel M, and Silman I (1993) Three-dimensional structure of acetylcholinesterase and of its complexes with anticholinesterase drugs. Chem Biol Interact 87:187-197.
36. Tanizawa A, Fujimori A, Fujimori Y, and Pommier Y (1994) Comparison of topoisomerase I inhibition, DNA damage and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst 86:836-842.
37. Wallace AC, Laskowski RA, and Thornton JM (1995) LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Prot Engineer 8:127-134.
38. Webb JL (1963) Enzyme and Metabolic Inhibitors. Volume 1. General Principles of Inhibition, p 57, Academic Press, New York.
39. Wlodek ST, Antosiewicz J, McCammon JA, Straatsma TP, Gilson MK, Briggs JM, Humblet C, and Sussman JL (1996) Binding of tacrine and 6-chlorotacrine by acetylcholinesterase. Biopolymers 38:109-117.
40. Yoon KJ, Krull EJ, Morton CL, Bornmann WG, Lee RE, Potter PM, and Danks MK (2003) Activation of a camptothecin prodrug by specific carboxylesterases as predicted by quantitative structure-activity relationship and molecular docking studies. Mol Cancer Ther 2:1171-1181.